Alberto Zambon Articles

Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Alberto Zambon
read more »

ODYSSEY trials at ESC Congress Hotline
ESC Congress 2014: Lipids Hotline: ODYSSEY TRIALS Prof Alberto Zambon, University of Padua, Italy discusses the four ODYSSEY trials with the PCSK9 inhibitor alirocumab presented at ESC Congress Hotline Sunday. Addition of a new investigational agent – Alirocumab – to high doses of statins result…
read more »